17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Among women with twin or triplet pregnancies, weekly injections of
17-alpha-hydroxyprogesterone caproate (17OHP), started before 24 weeks of gestation, will
reduce neonatal morbidity by reducing the rate of preterm delivery.
This study involves two concurrent double-blinded randomized clinical trials of 17OHP versus
placebo. Each trial will test the efficacy and safety of 17OHP in women with a specific risk
factor for preterm birth. The two risk factors to be studied are:
1. Twin pregnancy
2. Triplet pregnancy